Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DN8F1Z
|
|||
| Drug Name |
AR-301
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Ventilator-associated pneumonia [ICD-11: PK81.0] | Phase 3 | [1] | |
| Hospital-acquired pneumonia [ICD-11: CA40.Z] | Phase 2 | [2] | ||
| Pneumonia [ICD-11: CA40; ICD-10: J15.211] | Phase 1/2 | [3] | ||
| Company |
Aridis Pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Staphylococcus Alpha-hemolysin (Stap-coc hly) | Target Info | Inhibitor | [4] |
| Reactome | The NLRP3 inflammasome | |||
| WikiPathways | Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03816956) Adjunctive Therapy to Antibiotics in the Treatment of S. Aureus Ventilator-Associated Pneumonia With AR-301 (AR-301-002). U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT01589185) Safety, Pharmacokinetics and Efficacy of KBSA301 in Severe Pneumonia (S. Aureus). U.S. National Institutes of Health. | |||
| REF 3 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036003) | |||
| REF 4 | Clinical pipeline report, company report or official report of Aridis Pharmaceuticals. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.